

Date of publication: 10th November 2009


Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 29 - 2009

Relenza (Zanamivir)

Applies to the Living and Deceased Tissue Donor Selection Guidelines

Obligatory	Must not donate if: a) Taking relenza as treatment for influenza. b) At any time in the seven days prior to, or whilst taking relenza, the donor has had symptoms of influenza (a temperature of greater than 38 °C, or a history of fever and two or more of the following symptoms: cough, headache, runny nose, diarrhoea/ vomiting)
Discretionary	If the potential donor is taking relenza as prophylaxis, has not been advised to be confined to home, and has had no symptoms of influenza, accept.
See if Relevant	Infection – Acute
Additional Information	Relenza is a viral neuraminidase inhibitor (neuraminidase is an enzyme that helps the virus spread from cell to cell). It is used for post-exposure prophylaxis of influenza. It appears to be a very safe drug with little evidence for teratogenic (potential to cause birth defects) or mutagenic (potential to cause malignancy) effect.
Reason for Change	This is a new entry.



Dr Sheila MacLennan
Professional Director - Joint UKBTS/NIBSC Professional Advisory Committee
☎ Direct Dial: (0113) 214 8638 ✉ sheila.maclennan@nhsbt.nhs.uk